Technical Analysis for CALA - Calithera Biosciences, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| Historical CALA trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| New 52 Week Closing Low | Bearish | 0.00% | |
| Spinning Top | Other | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | -2.27% | |
| Oversold Stochastic | Weakness | -1.83% | |
| New 52 Week Closing Low | Bearish | -0.92% | |
| New 52 Week Low | Weakness | -0.92% | |
| Wide Bands | Range Expansion | -0.92% | |
| Down 3 Days in a Row | Weakness | -0.92% | |
| Lower Bollinger Band Touch | Weakness | -0.92% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| 60 Minute Opening Range Breakout | 1 day ago |
| Down 3% | 1 day ago |
| Down 2 % | 1 day ago |
| Down 1% | 1 day ago |
| Fell Below Previous Day's Low | 1 day ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 03/16/2021
Calithera Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. Its lead product candidate includes CB-839, an inhibitor of glutaminase, which is in three Phase I clinical trials for the treatment of patients with solid tumors, leukemias, lymphomas, and multiple myeloma. The company was founded in 2010 and is headquartered in South San Francisco, California.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Immunology Solid Tumors Treatment Of Cancer Oncology Lymphoma Hematology Tumor Metabolism Multiple Myeloma Targeted Therapy Anatomical Pathology Phosphoinositide 3 Kinase Inhibitor Leukemias Glutaminase
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Immunology Solid Tumors Treatment Of Cancer Oncology Lymphoma Hematology Tumor Metabolism Multiple Myeloma Targeted Therapy Anatomical Pathology Phosphoinositide 3 Kinase Inhibitor Leukemias Glutaminase
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 7.42 |
| 52 Week Low | 2.08 |
| Average Volume | 992,437 |
| 200-Day Moving Average | 3.81 |
| 50-Day Moving Average | 2.75 |
| 20-Day Moving Average | 2.42 |
| 10-Day Moving Average | 2.31 |
| Average True Range | 0.14 |
| ADX | 48.69 |
| +DI | 6.84 |
| -DI | 31.50 |
| Chandelier Exit (Long, 3 ATRs ) | 2.53 |
| Chandelier Exit (Short, 3 ATRs ) | 2.49 |
| Upper Bollinger Band | 2.75 |
| Lower Bollinger Band | 2.09 |
| Percent B (%b) | 0.09 |
| BandWidth | 27.25 |
| MACD Line | -0.17 |
| MACD Signal Line | -0.15 |
| MACD Histogram | -0.0132 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 2.26 | ||||
| Resistance 3 (R3) | 2.27 | 2.23 | 2.24 | ||
| Resistance 2 (R2) | 2.23 | 2.20 | 2.23 | 2.24 | |
| Resistance 1 (R1) | 2.19 | 2.18 | 2.17 | 2.19 | 2.23 |
| Pivot Point | 2.16 | 2.16 | 2.15 | 2.15 | 2.16 |
| Support 1 (S1) | 2.12 | 2.13 | 2.10 | 2.11 | 2.07 |
| Support 2 (S2) | 2.08 | 2.11 | 2.08 | 2.06 | |
| Support 3 (S3) | 2.04 | 2.08 | 2.06 | ||
| Support 4 (S4) | 2.04 |
